ALFA Finder| Management target | Revenue FY27 |
|---|
| Revenue growth | 17.8% YoY for Q1FY27. |
|---|---|
| Margins | EBITDA margin improved from 17.4% to 20.4% YoY. |
| Demand visibility | Strong; 3 million bed shortfall in India supports long-term growth. |
| Management confidence | High; focusing on 25% ROCE and capacity expansion. |
Growth
Revenue grew 17.8% YoY; PAT jumped 65.7% YoY to ₹12.7 Cr. ARPOB increased to ₹42,350.
Outlook
Targeting 1,000+ beds by FY27 via asset-light expansion. Raipur breakeven expected by Q3 FY27.
Risks
Low occupancy at the new Raipur facility (17.4%) and overall network occupancy decline to 45.5%.
Last quarter's promises, checked
Delivered
- Targeted 20.2% EBITDA margin → delivered 20.4% (= BEAT)
- Guided 15% revenue growth → delivered 17.8% (= BEAT)
- Targeted Salt Lake occupancy ~70% → delivered 70% (= BEAT)
Partly delivered
- Guided ARPOB growth 7-8% → delivered ~8% increase to ₹42,350 (= BEAT)
Missed
- Targeted Raipur occupancy 30% by year-end → delivered 17.4% (= MISS)
Investor Presentation filed with BSE, NSE: GPTHEALTH. Summary written with AI assistance from the document.
GPT Healthcare Ltd: key numbers
- Share price
- ₹145.02
- Market cap
- ₹1,190 Cr
- Revenue (annual)
- ₹472.6 Cr
- Net profit (annual)
- ₹42.22 Cr
- P/E (TTM)
- 22.9×Sector 54.5×
- Promoter holding
- 65.57%+0.00% QoQ
- FII holding
- 3.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GPT Healthcare Ltd
All →GPT Healthcare Earnings Call Transcript: Key Takeaways
Q2 revenue rose 14.1% to ₹135.6 Cr and EBITDA 23.9%, driven by occupancy and volume. Raipur break-even slipped from Q3 FY27 to Q1 FY28 amid ~₹9 Cr Q2 losses. Management gave no new quantified targets beyond FY27 growth.
GPT Healthcare Results Update
GPT Healthcare filed a press release on unaudited Q2 and H1 FY27 results, reporting H1 total income of Rs 266.8 Cr and PAT of Rs 28.1 Cr. The release carries a P&L highlights table without the full SEBI results statement.
GPT Healthcare Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹135.6 Cr (+14.0%), EBITDA ₹29.8 Cr (21.5% margin), PAT ₹15.4 Cr (+45.2%). H1 PAT ₹28.1 Cr (+53.9%). Eastern India expansion; 1,000-bed target.
GPT Healthcare Dividend
GPT Healthcare's board declared an interim dividend of ₹1.00 per share for FY2026-27. Record date is November 12, 2026, with payment expected by December 4, 2026.
GPT Healthcare Q2 FY27 Results: Net Profit ₹15.4 Cr, Up 45.3% YoY
GPT Healthcare approved unaudited Q2 and half-year results, with H1 revenue of Rs 26,182.60 lakh. A 10% interim dividend was declared with a November 12 record date.
- Key figure
- Net profit ₹15.4 Cr · +45.3% YoY
GPT Healthcare Board Meeting Date
GPT Healthcare will hold a board meeting on 05 Nov 2026 to consider Q2 and half-year unaudited results and a possible interim dividend for FY 2026-27. Trading window stays closed until 07 Nov 2026.